Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.10.0.1
Earnings (Loss) Per Common Share (Tables)
 6 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
 
Three Months ended

December 31,
 
 
Six Months ended

December 31,
 
 
 
2018
 
 
2017
 
 
2018
 
 
2017
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to iBio, Inc.
 
$
(4,469
 )
 
$
(3,899
)
 
$
(8,867
)
 
$
(7,725
)
  Preferred stock dividends
 
 
65
 
 
 
65
 
 
 
131
 
 
 
131
 
Net loss available to iBio, Inc. stockholders
 
$
(4,534
 )
 
$
(3,964
)
 
$
(8,998
)
 
$
(7,856
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
18,688
 
 
 
9,661
 
 
 
18,291
 
 
 
9,613
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per share amount
 
$
(0.24
)
 
$
(0.41
)
 
$
(0.49
)
 
$
(0.82
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
As of December 31, 2018 and 2017, shares issuable which could potentially dilute future earnings were as follows:
 
 
 
Three and Six

Months Ended

December,
 
 
 
2018
 
 
2017
 
 
 
(in thousands)
 
Stock options
 
 
1,311
 
 
 
1,360
 
Series A Preferred
 
 
5,603
 
 
 
-
 
Series B Preferred
 
 
6,428
 
 
 
-
 
Shares excluded from the calculation of diluted loss per share
 
 
13,342
 
 
 
1,360